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Abstract
MSTO1 encodes a cytosolic mitochondrial fusion protein, misato homolog 1 or MSTO1. While the full genotype–phenotype spectrum remains to be explored, pathogenic variants in MSTO1 have recently been reported in a small number of
patients presenting with a phenotype of cerebellar ataxia, congenital muscle involvement with histologic findings ranging
from myopathic to dystrophic and pigmentary retinopathy. The proposed underlying pathogenic mechanism of MSTO1related disease is suggestive of impaired mitochondrial fusion secondary to a loss of function of MSTO1. Disorders of
mitochondrial fusion and fission have been shown to also lead to mitochondrial DNA (mtDNA) depletion, linking them
to the mtDNA depletion syndromes, a clinically and genetically diverse class of mitochondrial diseases characterized by a
reduction of cellular mtDNA content. However, the consequences of pathogenic variants in MSTO1 on mtDNA maintenance
remain poorly understood. We present extensive phenotypic and genetic data from 12 independent families, including 15
new patients harbouring a broad array of bi-allelic MSTO1 pathogenic variants, and we provide functional characterization
from seven MSTO1-related disease patient fibroblasts. Bi-allelic loss-of-function variants in MSTO1 manifest clinically
with a remarkably consistent phenotype of childhood-onset muscular dystrophy, corticospinal tract dysfunction and earlyonset non-progressive cerebellar atrophy. MSTO1 protein was not detectable in the cultured fibroblasts of all seven patients
evaluated, suggesting that pathogenic variants result in a loss of protein expression and/or affect protein stability. Consistent
with impaired mitochondrial fusion, mitochondrial networks in fibroblasts were found to be fragmented. Furthermore, all
fibroblasts were found to have depletion of mtDNA ranging from 30 to 70% along with alterations to mtDNA nucleoids.
Our data corroborate the role of MSTO1 as a mitochondrial fusion protein and highlight a previously unrecognized link to
mtDNA regulation. As impaired mitochondrial fusion is a recognized cause of mtDNA depletion syndromes, this novel link
to mtDNA depletion in patient fibroblasts suggests that MSTO1-deficiency should also be considered a mtDNA depletion
syndrome. Thus, we provide mechanistic insight into the disease pathogenesis associated with MSTO1 mutations and further
define the clinical spectrum and the natural history of MSTO1-related disease.
Keywords MSTO1 · Mitochondrial fusion · Cerebellar atrophy · Muscular dystrophy · MtDNA depletion
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Introduction
Mitochondria maintain and express their own genome
(mtDNA), typically present in 100–1000 copies per cell and
organized into nucleoprotein structures known as nucleoids
[5, 18]. The mtDNA encodes thirteen subunits of the oxidative phosphorylation (OXPHOS) machinery that are essential
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for mitochondrial respiration and ATP production [39]. The
relative amount of mtDNA per cell varies in a tissue-specific
manner, as an adequate number of mtDNA copies must be
maintained to support aerobic respiration and meet cellular energetic demands [24]. As such, reduction in the total
amount of mtDNA clinically manifests as severe multi-systemic abnormalities to which energy-demanding organs, such
as the brain and muscles, are particularly susceptible.
MtDNA depletion syndromes are a clinically and genetically diverse class of mitochondrial diseases characterized
by a reduction of mitochondrial genomes [14, 33]. Of the 15
formally defined mtDNA depletion syndromes listed in The
Online Mendelian Inheritance in Man database (OMIM) [4],
most are caused by pathogenic variants in proteins that are
required for mtDNA replication (POLG, C10orf2, MGME1,
and TFAM) or those that are necessary to maintain mitochondrial deoxyribonucleoside triphosphates (dNTP) pools
(TK2, DGUOK, RRM2B, TYMP, SUCLA2, SUCLG1,
AGK, MPV17 and SLC25A) [14, 48]. However, pathogenic
variants in proteins that regulate the processes of mitochondrial fusion and fission have also been linked to mtDNA
depletion. These include the fusion protein OPA1 (OMIM
616896), as well as MFN2 and DNM1L, which are essential
for fusion and fission, respectively [25, 34, 41, 46, 49].
While defects in mtDNA replication or impaired maintenance of mitochondrial dNTP pools are expected to lead to
mtDNA depletion, it is less clear how mitochondrial fusion
and fission are involved in the regulation of mtDNA. Nonetheless, abnormalities in mtDNA integrity and nucleoid
distribution have been demonstrated in several models of
defective fusion. Mitochondrial membrane fusion is orchestrated by the activity of large GTPases, including Mitofusin
1 and 2 (MFN1, MFN2) localized to the outer membrane,
and Optic Atrophy 1 (OPA1) in the inner mitochondrial
membrane. In yeast, cells lacking the Mitofusin homolog
Fzo1p suffer from complete loss of mtDNA [21]. Meanwhile, knockout fibroblasts for OPA1, MFN1 and/or MFN2
display fragmented mitochondrial networks with altered
nucleoid distribution whereby some fragments are devoid of
mitochondrial genomes [10]. Finally, in humans, pathogenic
variants in MFN2 and OPA1 cause severe mtDNA depletion
and multiple mtDNA deletions [41, 46, 49]. Patients with
pathogenic variants in MFN2 or OPA1 that are associated
with mtDNA impairments have been reported to present
with a phenotype of early-onset ataxia, hypotonia, axonal
sensorimotor neuropathy, optic atrophy and hearing loss [2,
3, 22, 41, 46, 49].
Recently, MSTO1 was described as a cytosolic mitochondrial fusion protein, and pathogenic variants in MSTO1 have
been reported to cause ataxia, muscle weakness, cerebellar
atrophy and pigmentary retinopathy [16, 31, 36]. Notably,
these phenotypic features have all been previously reported
in mtDNA depletion syndromes [3, 14, 22]. To date, five
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independent studies have described MSTO1 variants in 12
patients from seven families [6, 16, 31, 36]. While pathogenic MSTO1 variants have been linked to impairments in
mitochondrial fusion, the consequence of these variants on
mtDNA maintenance and its associated clinical spectrum
has not been studied extensively.
In this study, we present an extensive phenotypic characterization of 15 new patients from 12 families harbouring
a broad array of bi-allelic pathogenic variants in MSTO1
confirming a remarkably consistent and ultimately recognizable clinical phenotype. Additionally, in cultured fibroblasts
from seven patients with MSTO1-related disease, we demonstrate loss of MSTO1 protein, significantly fragmented mitochondrial networks, enlarged lysosomal vacuoles, depletion
of mtDNA, and alterations to mtDNA nucleoids. Therefore,
we demonstrate that bi-allelic loss-of-function variants in
the mitochondrial fusion protein MSTO1 impair mtDNA
maintenance and fusion and result in mtDNA depletion in
fibroblasts, which we establish is associated with a remarkably consistent clinical spectrum of MSTO1-deficiency.

Materials and methods
Human subjects and samples
Patients were ascertained through their local neurology and
genetics clinics. F2 was identified through GeneMatcher
[45]. Written informed consent and age-appropriate assent
for study procedures and photographs were obtained by a
qualified investigator (protocol 12-N-0095 approved by the
National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Research Ethics Board of the
Hospital for Sick Children, REB # 1000009004: SCHN
Human Ethics Committee 10/CHW/45, University of Calgary Conjoint Health Research Ethics Board). Medical history was obtained and clinical evaluations, including brain
MRI and muscle biopsy, were performed as part of the
standard diagnostic evaluation. Muscle biopsy slides and
available electron microscopy images (EM) were reviewed
by investigators. DNA, muscle and skin biopsy samples were
obtained according to standard procedures.

Cell culture
Control and patient fibroblasts were generated from skin
biopsies and cultured in MEM media (Gibco, 11095080)
containing l-Glutamine and supplemented with 10% foetal bovine serum (FBS). HeLa cells were grown in DMEM
(Gibco, 11965092) supplemented with 10% FBS. Cells
were maintained at 37 °C and 5% C
 O2. HeLa cells were
transfected with a mammalian expression vector containing MSTO1-V5 (DNASU, HsCD00440595) using
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Lipofectamine 3000 (Thermo Fisher Scientific, L3000015)
according to manufacturer’s instructions. Briefly, cells were
seeded at 4.5 × 105 in 6-well plates and allowed to grow
overnight. The following day, 2 µg of plasmid were used
for transfections and cells were left to grow for 24 h before
harvesting.
For genetic rescue experiments, fibroblasts were electroporated with an MSTO1-P2A-mCherry construct using
the Amaxa Nucleofector II system (Lonza). The MSTO1
sequence was cloned into an AmCyan-P2A-mCherry construct (AmCyan-P2A-mCherry was a gift from Ilpo Huhtaniemi, Addgene plasmid # 45350; http://n2t.net/addge
ne:45350; RRID:Addgene_45350) [40], replacing the
mCyan sequence with the MSTO1 sequence. An empty vector containing only mCherry was also generated. Fibroblasts
grown to 70–80% confluence were resuspended in OptiMEM
media. Next, 1 × 106 cells in 100 µL media and 2 µg of
plasmid DNA were transferred to a sterile 2 mm electroporation cuvette (VWR 89047-208) and electroporated using the
A-024 program. Cells were then plated onto 35 mm glass
bottom dishes or in 100 mm dishes and incubated for 48 h
prior to further analysis.

mtDNA copy number analysis

Cell sorting

Immunofluorescence staining

Following electroporation with either mCherry empty vector
or MSTO1-P2A-mCherry, approximately 4 × 106 fibroblast
cells were sorted for red fluorescence (and MSTO1 expression) using a 130-µm nozzle on a BD FACSAria Fusion
(FACSAriaIII) cytometer (BD Biosciences), supported by
FACSDiva Version 8.0.1. Genomic DNA was subsequently
purified from control and patient mCherry-positive cells as
described below.

Fibroblasts were seeded on 12 mm glass coverslips (no. 1.5)
at 2X104 cells and allowed to grow for 24 h. Cells were subsequently fixed and stained with primary antibodies against
TOMM20 (Santa Cruz Biotechnology, FL-145) and LAMP1
(Santa Cruz Biotechnology, 18821) in addition to appropriate Alexafluor-conjugated secondary antibodies (Thermo
Fisher Scientific) at 1:1000 as done previously [42].

Western blot
For Western analyses, 3 × 1 05 cells were seeded in 100 mm
plates, allowed to grow for 2–3 days, harvested by trypsin
digestion, washed with 1X phosphate-buffered saline (PBS)
and lysed with RIPA buffer containing protease inhibitors.
Total cell lysates (50 µg) were resolved on SDS-PAGE gels
and transferred onto PVDF membranes. Blots were subsequently probed with the following antibodies (1:1000
dilution unless otherwise indicated): anti-MSTO1 (Genetex, GTX105110) (1:500), anti-V5 (Millipore, AB3792),
anti-Mitofusin1 (Cell Signalling, 14739), anti-Mitofusin2
(Abnova, H00009927-M03), anti-Opa1 (BD Bioscience,
612606), anti-Actin (Sigma A5316), anti-HSP60 (Cell Signalling, 12165), VDAC1 (Abcam, ab14734) and the appropriate horseradish peroxidase (HRP)-conjugated secondary
antibodies (1:3000). Blots were incubated with Clarity ECL
substrate (Biorad, 1705061) and imaged on an Amersham
Imager AI600.

Total genomic DNA (gDNA) (nuclear and mitochondrial
DNA) was extracted from control and patient fibroblasts
using the PureLink Genomic DNA Mini Kit (Thermo Fisher
Scientific, K182001) according to manufacturer’s instructions. Relative mtDNA copy number was analysed by realtime quantitative PCR (qPCR) using the QuantStudio 6 Flex
Real-Time PCR system (Thermo Fisher Scientific). Primer
sequences specific to mtDNA, nuclear-encoded housekeeping gene 18S and thermocycling conditions were performed
as described previously [13].
QPCR reactions were prepared to a total of 20 uL per
reaction containing 10 uL PowerUp SYBR Green Master
Mix (Thermo Fisher Scientific, A25742), 100 ng gDNA and
500 nM forward and 500 nM reverse primers. MtDNA copy
number relative to 18S was analysed using the delta delta
Ct method and represented as percent control [32]. Relative
mtDNA copy number was presented as mean ± SD from at
least three independent biological replicates and unpaired,
2-tailed Student’s t tests were used to determine statistical
significance.

Live cell imaging
In order to visualize mitochondrial DNA nucleoids, fibroblasts were stained with PicoGreen (Thermo Fisher Scientific, P7581) as described previously [7]. Briefly, cells were
seeded on glass bottom dishes (Mattek, P35G-1.5-14-C) at
8 × 104 and incubated overnight. Approximately 1 h prior
to imaging, cells were stained with PicoGreen at 3 µL/
mL for 30–45 min at 37 °C. MitoTracker Red dye (50 nM)
(Thermo Fisher Scientific, M7512) or MitoTracker Deep
Red dye (50 nM) (ThermoFischer Scientific, M22426) was
also added to the media to visualize mitochondrial networks.
The media containing dyes was aspirated, cells were washed
four times in pre-warmed 1XPBS, and fresh pre-warmed
media was added to the cells.

Microscopy
Images from both fixed and live samples were acquired on an
Olympus spinning disc confocal system (Olympus SD OSR)
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(UAPON 100XOTIRF/1.49 oil objective) operated by Metamorph software. A cell Vivo incubation module was used to
maintain cells at 37 °C and 5% CO2 during live cell imaging.

Image analysis
Mitochondrial networks
Mitochondrial morphology was qualitatively analysed by classifying networks into one of four categories, as previously
described [16]. For each fibroblast line, at least 50 cells were
scored, and the analyses were performed on three independent
replicates. Results represent mean ± SD, and P values were
based on unpaired, 2-tailed Student’s t tests.
MtDNA nucleoids
Mitochondrial DNA nucleoid size and number were analysed
in 35 fibroblast cells from each patient line and control using
the particle analysis tool in ImageJ FIJI [43]. First, images
were acquired using the same acquisition parameters, scaled
and binarized. For each cell, a region of interest (ROI) encompassing the entire mitochondrial network was selected. Then,
in binarized mtDNA nucleoid images, the particle analysis tool
was used to measure surface area and total nucleoid counts
within the selected ROI. Nuclear signal was excluded from the
analysis. Nucleoid sizes are presented as the average size of all
nucleoids per cell in a violin plot, highlighting the distribution
of quantified mtDNA nucleoid sizes. The non-parametric Kolmogorov–Smirnov (K–S) test was used to determine statistical
significance regarding the distribution of nucleoid sizes. The
relative frequencies of nucleoid sizes were assessed in each
quantified cell and the percentage of large nucleoids (> 0.2
µm2) in control and patient fibroblasts was plotted. Nucleoid counts represent mean ± SD, and P values were based on
unpaired, 2-tailed Student’s t tests.
Lysosomes
The presence of enlarged lysosomal aggregates was quantified
from confocal images of patient and control cells by scoring
the number of cells with normal vs. enlarged lysosomes. At
least 50 cells were analysed per fibroblast line from two independent replicates. Results represent mean ± SD, and P values
were obtained from unpaired, 2-tailed Student’s t tests.

Results
Clinical characteristics
The clinical presentation of the 15 patients, which includes
nine females and six males, is summarized in Table 1, with
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ages ranging from 6 to 52 years at the time of most recent
examination. There were two families with more than one
affected relative: Family 1 (F1) consists of three affected
sisters [P1, P2, P3; p.(Asp236His); p.(Arg279His)], and
Family 2 (F2) consists of two affected siblings [P4, P5;
p.(Gly420ValfsX2); p.(Arg256Gln)] (Fig. 2d). Family history was non-contributory in the remaining patients of the
cohort.
Patients typically presented with hypotonia and delayed
motor milestones with first symptoms recognized between
birth and three years of age. All but five patients presented
with delayed motor milestones and then subsequently
achieved independent ambulation with gaits characterized as
waddling-like and wide-based across the entire cohort. All
15 patients reported either relatively slow progression or no
progression of their muscle weakness. At the time of the last
examination, all were found to have predominantly proximal
weakness. Cerebellar symptoms manifested as dysmetria in
11, gait ataxia in nine and abnormal speech in 12, which
included a history of speech delay in five and dysarthria
in eight patients, respectively. Corticospinal tract manifestations including increased tone, the presence of a spastic
catch, clonus and/or increased deep tendon reflexes were
observed in eight patients. A history of learning difficulties was reported in nine patients while none of the patients
were found to have major cognitive involvement. None of
the patients had a history of seizures, cataracts, hearing or
cardiac involvement.
Electrophysiological studies were available for four
patients. Three [P4: p.(Gly420ValfsX2); p.(Arg256Gln), P5:
p.(Gly420ValfsX2); p.(Arg256Gln), P10; p.(Asp236Gly);
p.(Arg279His)] of the four had evidence of myotonia on
EMG, and complex repetitive discharges were present in P8
[p.(Phe217Leu); p.(Asp236His)]. Lower extremity muscle
MRI imaging was available for four patients and revealed a
spectrum of involvement ranging from severe involvement
of the muscles of the upper leg with apparent fatty replacement of all muscles except for the semimembranosus and
the biceps femoris (P6; p.(Asp236His); p.(Phe217Leu)) to
mild fatty infiltration of upper and lower leg muscles [P10;
p.(Asp236Gly); p.(Arg279His)] (Table 1; Fig. 1a). Pulmonary function testing was performed in nine patients and
revealed reduced forced vital capacity (FVC) measurements,
ranging from 60 to 79% predicted. Serum creatine kinase
(CK) levels were significantly increased in all patients,
except for P15, ranging from 300 to 5000 U/L. Echocardiogram was normal in the 11 patients who underwent this
screening evaluation.
Overall, we recorded a remarkably consistent clinical
phenotype of primary motor developmental delay, fairly stable mostly proximal muscle weakness caused by a muscular
dystrophy, mild cerebellar findings of dysmetria, ataxia and
dysarthria based on a stable congenital cerebellar atrophy,

Reflexes
3 + UE,
4 + LE
with
spreading

Corticospi- Clonus
nal tract
involvement

–

Speech
delay

Speech
Speech
involvedelay
ment

–

Learning
difficulties

Cognitive –
involvement

Swallowing
difficulties

+ Mild dysmetria

Cerebellar +
symptoms

WideSlightly
based,
ataxic,
waddlingmildly
like,
Trendedifficullenburg,
ties with
difficultandem
ties with
gait
tandem
gait

Proximal
weakness;
mild
facial
weakness

Muscle
Proximal
strength
weak(MRC)
ness (3/5
range)

Gait

Delayed;
walked at
2 years

Motor
Delayed;
develop- walked
ment
between
2.5 and 3
years

6 months

–

Dysarthria

Learning
difficulties

+ Mild dysmetria

Delayed;
walked at 8
years

Congenital

African

F/21

Delayed;
walked at
22 months

Congenital

Caucasian

M/37

Increased tone
in UE and
LE; reflexes
3+

+

Dysarthria

Learning difficulties

+ Dysmetria;
tremor

–

+ Dysmetria;
tremor

+

Dysarthria

–

–

–

Waddlinglike

Learning difficulties

Proximal
weakness
(3/5 range);
mild facial
weakness

Delayed;
pulled-tostand at 18
months

Congenital

Caucasian

M/9

Mild
proximal
weakness

Delayed;
walked at
23 months

15 months

Caucasian

M/6

+

Speech delay

–

–

Dysarthria

–

+ Mild
dysmetria

Wide-based,
Wide-based;
waddlingunable to
like with
do tandem
bilateral
gait
foot drop
and circumduction;
unable to
do tandem
gait
+ Dysmetria

P9

P10

P11

P12

P13

P14

+

Speech
delay

Learning
difficulties

+ Mild dysmetria

Ataxic,
widebased;
unable
to do
tandem
gait

Normal
(reflexes
2+)

Proximal
weakness

Delayed;
walked at
4 years

1 year

Chinese

F/19

+

Dysarthria

–

+ Slight
tremor

Wide-based,
waddlinglike

Babinski,
clonus,
spastic
catch;
reflexes
3+

Proximal
weakness (3/5
range);
mild facial
weakness

Normal

Congenital

Caucasian/
Hispanic

F/16

–

–

–

–

Trendelenburg,
difficulties
with tandem gait

Clonus;
reflexes
3+ with
spreading

Proximal
weakness

Normal

2 years

Caucasian

F/20

–

Wheelchair
for longer
distances

Absent deep
tendon
reflexes

Proximal
weakness
(3/5 range)

Normal

18 months

Caucasian

M/23

–

Dysarthria

–

–

Learning dif- Learning difficulties
ficulties

+ Dysmetria
and tremor

Ataxic,
widebased,
unsteady

Normal
(reflexes
2+)

Proximal
weakness

Delayed;
walked at
2.5 years

1 year

Chinese

F/6

Unknown

Dysarthria

–

Dysarthria;
Speech
delay

Learning difficulties

+ Dysmetria

–

Learning difficulties

Ataxic,
widebased

Normal
(reflexes
2+)

Proximal
weakness

Normal

3 years

Native
American

F/7

c.40G>A;
p.G14R
c.225_
230del;
p.L76_
S77del

P15

Ambulatory

Unknown

Mild
proximal
weakness

Unknown

< 7 years

Caucasian

M/52

c.706G>C; c.1433A>G; c.707A > G;
c.706G>C;
c.1033C>T; c.651C>G;
c.651C>G;
p.D236H
p.Y478C;
p.D236G
p.D236H
p.R345H
p.F217L
p.F217L
c.651C>G; Missing sec- c.836G>A;
c.836G>A;
c.971C>T;
c.651C>G;
c.835C>T;
p.F217L
ond allele
p.R279H
p.R279H
p.T324l
p.F217L
p.R279C

P8

NorBabinski, clo- Normal
mal (reflexes nus, increased (reflexes
2+)
tone in LE;
2+)
reflexes
2 + (reduced
triceps)

Ataxic, widebased with
assistance

Increased
tone in LE;
reflexes 3+

UE proximal
UE proximal
Proximal
weakness (3/5
weakness (3/5
weakrange)
range)
ness (3/5
range);
mild facial
weakness

Delayed;
walked at 6
years

1 year

African

M/23

WideAtaxic, widebased,
based; cane
waddlingfor long
like,
distances
difficulties with
tandem
gait

Clonus;
reflexes
3 + with
spreading

Proximal
weakness
(hips and
shoulders
3-3 +/5)

Delayed;
walked at
2 years

6 months

Caucasian

F/12

6 months

Caucasian

F/17

Symptom
onset

P7

Caucasian

P6

Ethnicity

F2P5

F/19

F2P4

Sex/age
(years)

F1P3

c.706G>C; c. 706G>C; c.706G>C; c.1259delG;
c.1259delG;
c.706G>C;
c.1350G>C;
p.D236H
p.D236H
p.D236H c. p.G420VfsX2;
p.G420VfsX2;
p.D236H
p.L450F;
c.836G>A; c.836G>A; 836G>A;
c.767G>A;
c.767G>A;
c.651C>G;
Deletion
p.R279H
p.R279H
p.R279H
p.R256Q
p.R256Q
p.F217L

F1P2

Mutations

F1P1

Table 1  Clinical characteristics

Acta Neuropathologica (2019) 138:1013–1031
1017

13

13

Not performed

R vastus
lateralis
(7 years):
marked
variation
in fiber
size with
evidence
of fiber
type
grouping

(6 years):
Cerebellar
atrophy
involving
vermis
and both
hemispheres

EMG

Muscle
biopsy

Brain
MRI

(5 years):
Cerebellar
atrophy
involving
vermis
and both
hemispheres

Not performed

Not performed

500–788
959 (2
(16 years)
years)

F1P2

CK
(U/L)

F1P1

Table 1  (continued)

(2 years):
Cerebellar
atrophy
involving
vermis
and both
hemispheres

Not performed

Not performed

334 (2
years)

F1P3

Not performed

Myotonia (14
years)

1494 (16
months),
3196 (17
years)

F2P5

(2 years):
(16 months):
CerebelCerebellar atrophy
lar atrophy
involving verinvolving vermis and both
mis and both
hemispheres;
hemispheres;
(15 years):
(14 years): no
moderate
progression
to marked
of cerebellar
diffuse vermis
atrophy;
and cerebelincreased T2
lar volume
signal in the
loss; mild
peritrigonal
increased
white matter
FLAIR and
T2 signal of
the cerebellar
white matter
surrounding
the fourth
ventricle

R quadriceps (2
years): severe
atrophy of
type I fibres
and fiber
splitting

Myotonia
(15 years)

4550 (3 years),
3487 (18
years)

F2P4

Not performed

4387 (5
years)

P7

Complex
repetitive
discharges
(3 years)

600-951

P8

Not performed

4,029 (16
years)

P9

Myotonia (9
years and
13 years)

1451 (9
years),
1629 (12
years)

P10

Not performed

1200-1300 (3
years)

P11

Not performed

1867 (18
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2249 (3
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P12

Not performed
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Cerebellar
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involving
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both hemispheres
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involving
vermis and
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cerebellar
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Cerebellar
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atrophy
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involving
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(16 years):
no progression of
cerebellar
atrophy
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1450 (47
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(39 years):
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variation in
variation
fiber size
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size
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1450 (14
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P13
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atrophy
involving
both hemispheres;
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slight progression of
cerebellar
atrophy
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L deltoid
L biceps (9
L quadriceps R quadriceps
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Marked
(16
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variation in
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marked
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fiber size,
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fiber size,
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increased
variation
in fibre
fibre size,
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significant
size,
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size,
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Not performed

1192 (37
years)

P6

(5 years):
Cerebellar
atrophy
involving
vermis and
both hemispheres; (6
years): no
progression of
cerebellar
atrophy

Not performed

Not performed

107 (7 years)

P15
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Not performed

60%

NL (5
years)

Short
stature

Muscle
MRI

FVC %
predicted

Echocardiogram

Other

F1P1

Table 1  (continued)

Short
stature

Not performed

62%

Not performed

F1P2

Short
stature

Not performed

69%

Not performed

F1P3

None

NL

Not performed

Not performed

F2P4

None

NL

Not performed

Not performed

F2P5

P7

None

NL (37
years)

77% (37
years)

None

NL (9 years)

68% (7 years)

(37 years):
(9 years):
Diffuse
Fatty infilfatty
tration of
infiltration
all muscles
of all upper
bilaterleg musally with
cles except
relatively
for the
increased
semimeminvolvebranosus
ment of the
and biceps
adductor
femoris;
magnus
relative
bilaterally
sparing of
the soleus
and the
flexor hallucis longus with
prominent
atrophy of
the lateral
gastrocnemius
bilaterally

P6

P9

None

NL (6 years)

Longstanding
esotropia
and short
stature

NL (21
years)

64% (6 years) Not performed

(6 years):
Not perFatty
formed
infiltration
of all muscles with
relatively
increased
involvement of the
sartorius
when
compared
with the
gracilis and
prominent
atrophy of
the lateral
gastrocnemius
bilaterally

P8

P11

64% (18
years)

(16 years):
None
Anisoastigmatism
with mild
ambylopia
of the right
eye

NL (16 years) NL

71% (16
years)

(16 years):
Not perFatty
formed
infiltration
of all muscles with
increased
involvement of
the rectus
femoris
and
relatively
increased
involvement of the
sartorius
when
compared
with the
gracilis and
prominent
atrophy of
the lateral
gastrocnemius
bilaterally

P10

Short stature
and microcephaly

NL (3 years)

Not performed

Not performed

P12

62% (39
years)

Not performed

P14

None

Vasovagal
syncope
with
asystole

NL (14 years) NL (52
years)

79% (14
years)

Not performed

P13

None

NL (4 years)

Not performed

Not performed

P15
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Fig. 1  Muscle and brain imaging. a Lower extremity muscle MRI
of patients P6 [p.(Asp236His); p.(Phe217Leu)], P7 [p.(Leu450Phe);
deletion], P8 [p.(Phe217Leu); p.(Asp236His)] and P10
[p.(Asp236Gly); p.(Arg279His)] at ages 37 years, 9 years, 6 years
and 16 years, respectively. Abnormal signal intensity of muscles such
as the posterior gastrocnemius muscle in patient P6 (white arrow),
reflects muscle breakdown and replacement with adipose tissue. b
Brain MRI completed in 12 patients consistently demonstrates mod-

erate-to-severe cerebellar volume loss or hypoplasia involving the
vermis and both hemispheres. Repeat MRI images were available in
patients P4 [p.(Gly420ValfsX2); p.(Arg256Gln)], P8 [p.(Phe217Leu);
p.(Asp236His)], P10 [p.(Asp236Gly); p.(Arg279His)] and P12
[p.(Arg345His); p.(Thr324Ile)] demonstrate mild [P12] to no progression [P4, P8 and P10] of cerebellar volume loss over time (second
row)

mild pyramidal signs and evidence for some degree of
speech delay and learning disability in some. Meanwhile,
major cognitive involvement, seizures, retinopathy, optic
atrophy or hearing loss were not seen.

Muscle histopathology and electron microscopy

Neuroimaging characteristics
Brain MR imaging was available for 12 patients and consistently showed moderate to severe cerebellar atrophy/
hypoplasia involving the vermis and both hemispheres in
all 12 (Fig. 1b). Four of the brain MRIs had been performed
in patients before age 2 years, which revealed significant
decrease in cerebellar volume. A lack of progression of
cerebellar volume loss was confirmed through repeat imaging available in four patients. Patient 12 [p.(Arg345His);
p.(Thr324Ile)] showed mild progression of cerebellar volume loss between ages one and 6 years.
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Muscle biopsies were performed in ten patients and were
consistent with a dystrophic process with evidence of variation in fibre type size, a mild degree of necrosis and regeneration, internalized nuclei and whorled fibres (Fig. 2a).
Electron microscopy analysis was performed in three
patients. Aggregates of subsarcolemmal mitochondria were
noted in patients P9 [p.(Tyr478Cys); missing] and P10
[p.(Asp236Gly); p.(Arg279His)]. There was also evidence
of non-specific mitochondrial morphologic abnormalities
(variations in mitochondrial shape and size) seen in patients
P9 and P10 (Fig. 2b).

Molecular results
Using whole exome sequencing (WES), we identified apparent homozygous or compound heterozygous variants in
MSTO1 (NM_018116.3) in 15 patients from 12 independent families consistent with the bi-allelic recessive mode of
inheritance (Fig. 2c). Parental DNA for segregation testing

Acta Neuropathologica (2019) 138:1013–1031

1021

a
ii

iii

iv

ii

iii

iv

i

b
i

500 nm

500 nm

500 nm

c

d
cDNA
cDNA
Exon
Exon
cDNA Exon

Dominant
Dominant
Mutation
Mutation
Dominant Mutation

Tubulin
Tubulin
Domain
3 Domain
Tubulin
33 Domain

Recessive
Recessive
Mutation
Mutation
Recessive
Mutation

Misato
Misato
Segment
Segment
II
Misato
Segment
II II
Tubulin-Like
Tubulin-Like
Domain
Domain
Tubulin-Like
Domain

Deletion
Deletion
Mutation
Mutation
Deletion
Mutation

p.G14R
p.G14R

11 1

p.L76_S77del

2
2 2

33 3 44 4

p.R256Q
p.R256Q
p.R256Q

p.R345H
p.R345H

/.5$"*0EFG"

p.R345H
p.R279C
p.R279C

55 5 66 6

F2
p.R279H

p.G420VfsX2

p.R256Q

/.H$'(C
p.Y478C
p.Y478C

77 7 88 8

99 9

11 11
1010 11
10

121213
1313
12

p.

p.Q27*

p.D236H

/.9$%*8
p.L450F
p.L450F

p.F217L
p.F217L
p.F217L

p.V8M
p.V8M
p.V8M
p.Q27*
p.Q27*

F1

Exon
Exon
9 -14
9 -14
DelDel
IJK6L)LD!$L:32

p.D236H/G
p.D236H/G
p.D236H/G

C

500 nm

p.R279H
c.966+1G>A
p.R256W
p.R256W

p.R279H
p.R279H
c.966+1G>A
c.966+1G>A

p.G420VfsX2
p.G420VfsX2
c.1099-1G>A
p.F376L
p.F376L
p.R345C
c.1099-1G>A
c.1099-1G>A

1414
14

p.P479S
p.P479S

NM_018116.3
NM_018116.3
NM_018116.3

P1

P2

P3

P4

P5

p.D236H;
p.R279H

p.D236H;
p.R279H

p.D236H;
p.R279H

p.G420VfsX2;
p.R256Q

p.G420VfsX2;
p.R256Q

p.T324I
p.R345C
p.R345C
p.T324I
p.T324I

Fig. 2  Muscle biopsy, MSTO1 pathogenic variants and pedigrees.
a Histology findings from the vastus lateralis muscle biopsy of P7
[p.(Leu450Phe); deletion] at age 20 months include internalized
nuclei on hematoxylin and eosin (H&E) staining (white arrow) (i)
and variation in fiber size on nicotinamide dinucleotide (NADH)
staining (ii) and whorled fibres evident on Gömöri trichrome (inset)
(iii) and COX staining (white arrow) (iv). b Muscle biopsy electron
microscopy (EM) findings are notable for aggregates of subsarcolemmal mitochondria in both P9 [p.(Tyr478Cys); missing)] (i and ii) and
P10 [p.(Asp236Gly); p.(Arg279His)] (iii and iv) and non-specific
mitochondrial morphologic abnormalities (variations in mitochondrial shape and size) in P10. c Schematic of new and reported human

MSTO1 pathogenic variants. Shown in numbered light blue squares
are cDNA exons (RefSeq isoform NM_018116.3 of MSTO1). Corresponding known protein domains are shown in orange (tubulin 3
domain) and beige (Misato segment II tubulin-like domain). Variants
written in black text are recessive; the single mutation in red has been
previously reported to cause dominantly inherited MSTO1-related
disease. The top half of the figure depicts novel variants reported in
this publication; the bottom half of the figure depicts variants which
have been previously reported. Bolded variants depict previously
reported mutations that were also present in our cohort. The dotted
line depicts a large deletion (exons 9-14). d Pedigree of two families
consistent with recessive inheritance of MSTO1 pathogenic variants

was not available for P13, who was found to be apparently
homozygous for the common p.(Phe217Leu) variant. Six
of these missense variants have not yet been reported. The
p.(Gly420ValfsX2) frameshift variant was recently reported
[31]. There were three apparent recurring mutation hotspots
(p.Asp236, p.Arg279, p.Phe217), which were identified as
five, four and four independent alleles, respectively. The
p.(Arg279His) variant had been previously reported in heterozygosity with a second pathogenic allele in three families
[23, 31].
Trio WES identified an apparently homozygous
p.(Leu450Phe) MSTO1 pathogenic variant in P7. Targeted
sequencing confirmed that this variant was paternally

inherited, while the mother was found to be negative for
the variant. Subsequent testing using exon-level oligo CGH
array identified a presumed maternally inherited deletion
in P7 encompassing at least exons 9-14 of the MSTO1
gene and extending to include both the YY1AP1 as well
as the DAP3 genes (Genomic Coordinates: arr[GRCh37]
1q22(155582110_155708204)x1). Recessive pathogenic
variants in YY1AP1 have been reported in association with
Grange syndrome (OMIM 607860). DAP3 has not yet been
associated with human disease.
Tr io WES for P9 identif ied a heterozygous
p.(Tyr478Cys) MSTO1 variant inherited from a clinically
unaffected father. Whole genome sequencing (WGS) in
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P9 confirmed this heterozygous missense variant but did
not identify a second MSTO1 allele in compound heterozygosity. Exon-level oligo CGH testing for P9 was
normal. RNA sequencing (RNA-seq) analysis to identify
any possible transcriptional aberrations in MSTO1 for P9
was inconclusive, and no splice aberrations were identified in P9. Attempts to evaluate allele balance at the hg19:
chr1:155583319 variant via RNA-seq were unsuccessful
due to insufficient coverage in the region, likely due to
the presence of a highly homologous pseudogene.
Parental segregation testing for all MSTO1 variants was
consistent with bi-allelic recessive inheritance, except
for P9 (p.(Tyr478Cys); missing) in whom the presumed
maternally inherited allele has not yet been identified,
and for P13 (p.(Phe217Leu); p.(Phe217Leu)) in whom
parental DNA was not available. Variants identified were
predicted to be damaging and either absent or extremely
rare (allele frequency below 0.00005) in Genome Aggregation Database (GnomAD) and Exome Aggregation
Consortium (ExAC) except for the p.(Arg279His) variant.
This particular variant was listed with an allele frequency
of 0.00019 in ExAC and 0.00026 in GnomAD with one
reported homozygous individual [29]. MSTO1 variants are
scattered throughout the gene and do not seem to cluster
in a specific MSTO1 domain (Fig. 2c).

Characterization of patient fibroblasts
In order to further investigate the effect of MSTO1 mutations, we examined the expression of MSTO1 protein by
immunoblotting. As the MSTO1 antibody we used detects
multiple bands in fibroblast cells, we confirmed the size of
the correct band, which migrates at the predicted size of
62 kDa, corresponding to MSTO1 protein in HeLa cells
overexpressing a V5-epitope-tagged-MSTO1 or an empty
vector (Fig. 3a). Our data show that the MSTO1 protein is
undetectable in all patient fibroblasts, (n = 7) suggesting that
pathogenic variants affect protein expression and/or stability
(Fig. 3a). Although this observation was expected in cells
with large deletions encompassing the MSTO1 gene [e.g.
P7; p.(Leu450Phe); deletion)], it is intriguing that all patient
fibroblasts containing combinations of missense mutations
exhibit a similar cellular phenotype. It is also worth noting
that MSTO1 variants do not have gross effects on the expression of mitochondrial fusion proteins (MFN1/2 and OPA1)
(Fig. 3b).
Given the established role of MSTO1 as a mitochondrial fusion regulator [16, 36], we examined mitochondrial
morphology in seven MSTO1 patient fibroblasts. Consistent with previous reports, visualized mitochondrial networks in patient fibroblasts were fragmented compared
to control fibroblasts (Fig. 4). In addition, we examined
lysosomal structures in MSTO1 patient fibroblast lines by
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Fig. 3  Pathogenic variants lead to MSTO1 protein instability. a Western blot analysis of total cell lysates from control and patient fibroblast. As a control, total cell lysates from HeLa cells overexpressing
MSTO1-V5 or empty vector were also included. Blots were probed
with antibodies against endogenous MSTO1, VDAC1, HSP60 and
V5. Black arrow corresponds to endogenous MSTO1 protein further
verified in HeLa cell lysates; meanwhile, bands underneath are nonspecific. b Western blot analysis of cell lysates as in a. Blots were
probed against fusion proteins (Mfn1, Mfn2 and Opa1) and loading
controls

immunofluorescence, as mitochondrial dysfunction can also
cause alterations to lysosomes [12]. Compared to unaffected
control cells, we observed markedly enlarged lysosomal vacuoles across all MSTO1 patient lines (Fig. 5), an observation that has not been previously reported in the context of
MSTO1 dysfunction [16, 35].
As pathogenic variants in mitochondrial fusion proteins
MFN2 and OPA1 have been shown to cause mtDNA depletion [3, 49], we analysed mitochondrial genomes in patient
cells. We observed a significant reduction in mtDNA copy
number across all fibroblast lines, ranging from 30 to 70%
depletion (Fig. 6a). MtDNA nucleoids are nucleoprotein
assemblies involved in the organization and segregation
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Fig. 4  Characteristics of
MSTO1 patient fibroblasts.
a Representative confocal
microscopy images of control
and patient cells. Mitochondrial
networks in MSTO1 patient
cells are more fragmented
and contain fewer but larger
mtDNA nucleoids compared
to the control cells. Live cells
were stained with MitoTracker
Red (red, mitochondria) and
PicoGreen (green, nuclear
and mitochondrial DNA). b
Quantification of mitochondrial
morphology from control and
patient cells performed from
three independent replicates.
Statistical analysis was performed on the number of cells
with partly fragmented mitochondrial morphology in control versus patient cells; Student
T test, *p < 0.05, **p < 0.001

of mtDNA. While examining the size and distribution of
mtDNA nucleoids within the mitochondrial network in
MSTO1 patient fibroblasts, we found that the patient fibroblasts contained fewer nucleoids, which were larger in size
compared to control lines (Fig. 6b, c). Notably, several mitochondrial fragments were devoid of mitochondrial genomes
in patient cells (Fig. 4a), a phenotype previously reported in
cells lacking fusion regulation [10]. Together, these observations demonstrate significant alterations of the mitochondrial
genome in all patient fibroblast lines evaluated. Unfortunately, muscle tissue was not available for further mtDNA
content studies.
The similarity and consistency of the cellular phenotypes
described across all seven MSTO1 patient fibroblast lines
strongly support the notion that loss of MSTO1 function is
the underlying cause responsible for these observations. In
order to further confirm that the cellular phenotypes were
in fact due to the loss of MSTO1, we transiently expressed

wild-type MSTO1 in two of the patient cell lines (P4 and P7)
(Fig. 7a, b). Similar to previous reports [16, 35], we found
that expression of wild-type MSTO1 restored mitochondrial
morphology after 48 h (Fig. 7c). Notably, we also observed
more fused mitochondrial networks in control cells overexpressing MSTO1, further validating the role of MSTO1
in promoting fusion. In addition, we also see that lysosome
abnormalities are restored (Fig. 7d). While we observed
a significant rescue in MSTO1 fibroblasts with regard to
mtDNA nucleoid size (Fig. 7e), the number of mtDNA
nucleoids did not change in MSTO1 fibroblasts (Fig. 7f).
A potential confounding factor is that the transfection protocol itself causes a decrease in mtDNA nucleoid counts,
which could be masking a rescue. However, mtDNA copy
number was also not rescued after only 48 h (Fig. 7g). This
incomplete rescue of mtDNA nucleoid abundance and copy
number likely reflects the fact that it may take longer than
48 h for the mtDNA copy number to be re-established.
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Fig. 5  Enlarged lysosomal
vacuoles in MSTO1 patient
fibroblasts. a Representative
confocal images of control
and patient cells fixed and
stained with antibodies against
TOMM20 (red, mitochondria)
and LAMP1 (green, lysosomes).
Compared to an unaffected
control, patient cells contain
distinct lysosomal clusters. b
Quantification of cells containing enlarged lysosomes in
control and patient fibroblasts
performed from two independent replicates. Statistical
analysis was performed; Student
T test, *p <0.05

Collectively, our data suggest that various pathogenic variants in MSTO1 behave in a similar fashion and lead to mitochondrial abnormalities in patient cells, in particular with
regard to mtDNA, providing novel mechanistic insight into
the disease pathogenesis associated with MSTO1 mutations.

Discussion
Bi-allelic pathogenic variants in the nuclear-encoded cytosolic protein MSTO1 have been reported in 12 patients from
7 families to date [6, 16, 31, 36]. This study characterizes
12 families with an additional 15 affected patients and thus
presents the largest single cohort of patients with variants in
the cytosolic mitochondrial fusion regulator, MSTO1. The
series includes several novel pathogenic variants and allows
for further delineation of the recessive MSTO1-related disease-associated phenotype. We found this phenotype in our
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cohort to be remarkably consistent with childhood-onset,
fairly non-progressive muscle weakness and clinical evidence of corticospinal tract and cerebellar involvement. As
a corollary to this clinical presentation, an elevated CK level
associated with a histologically dystrophic myopathy and
early-onset/congenital yet stable cerebellar atrophy/hypoplasia is seen on testing. Clinical findings are similar to a
recently reported small case series of 12 patients with recessive MSTO1-related disease [6, 16, 23, 31, 35]. Pigmentary
retinopathy was previously observed as part of the recessive
phenotype [23, 35]. This finding was not reported in any of
the patients in our cohort; however, formal ophthalmologic
examination was not pursued in all patients. Arthrogryposis
was also previously reported in one patient [23]. While congenital onset hypotonia was noted in three of our patients,
no other abnormalities were reported at birth.
The delayed motor development seen in our patients
could be due to the cerebellum volume loss, the muscular
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Fig. 6  Pathogenic variants in MSTO1 are linked to mtDNA depletion.
a Relative mtDNA copy number normalized to the nuclear-encoded
18S gene. Data represent at least three independent biological replicates. b Analysis of mtDNA nucleoid counts per cell from 35 cells for
each group. c Quantification of nucleoid sizes in control and patient
cells. Data represent average nucleoid sizes from the same cells as in

b. Average mtDNA nucleoid size is presented in a violin plot. K–S
test was performed to determine statistical significance. d Frequency
of nucleoids larger than 0.2 µm2 in all 35 cells quantified per fibroblast line. Student T test was performed as indicated for a, c and d.
*p <0.05, **p <0.01, ***p <0.0001

dystrophy or more likely a combination of both. Review
of brain MRI imaging in our cohort demonstrated that the
decrease in cerebellar volume is evident in both hemispheres;
the volume loss in the vermis is present at a very young age
(as observed on the first MRIs obtained) and is non-progressive on follow-up imaging in the majority of patients. Hence,
it is possible that the cerebellar volume loss reflects more of
a hypoplasia rather than an early-onset progressive atrophy,
or a combination thereof. In early cerebellar hypoplasias that
interfere with normal cerebellar development, granule cell
proliferation deficiency as well as some granular cell loss
may underlie an overall smaller cerebellar cortical volume
[19]. This may be in keeping with the slight progression of
cerebellum volume loss seen in consecutive scans obtained
for P12 (p.(Arg345His); p.(Thr324Ile)) at ages 1 and 2 years,
which may be disproportionate to the overall brain volume
and reflective of a developmental process given that cerebellum growth continues after birth [1]. Without further
morphological autopsy data, the relative contributions of
hypoplasia versus atrophy will have to remain undetermined.

Clinically, it is reassuring that all patients achieved ambulation, which has been maintained at age 52 years in the oldest
patient reported to date with MSTO1-related disease [P14;
p.(Phe217Leu); p.(Arg279Cys)].
One of the most important diagnostic considerations in patients presenting with childhood-onset muscle
weakness, elevated CK and structural brain abnormalities with prominent cerebellar involvement, includes the
α-dystroglycanopathies (αDGs). The αDGs are a clinical
and genetic heterogenous sub-group within the congenital
muscular dystrophies (CMDs) that manifest as an earlyonset dystrophic muscle disease with central nervous system involvement, including abnormal neuronal migration
resulting in cortical malformations as well as impaired
synaptic function [17, 37]. Specifically, αDGs caused by
mutations in ISPD and GMPPB may manifest with phenotypes reminiscent of recessive MSTO1-related disease [9,
11, 17]. However, hypoglycosylation of α-dystroglycan is a
distinctive marker for the αDGs that can be detected using
specific antibodies against the matriglycan glycoepitope
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Fig. 7  Expression of wild-type MSTO1 rescues cellular phenotypes
in MSTO1 patient fibroblasts. Control, P4 and P7 fibroblast cells
were transfected with MSTO1-P2A-mCherry or the mCherry empty
vector control. Representative images of fibroblasts transfected
with MSTO1-P2A-mCherry, for a live cells stained with picogreen
and MitoTracker Deep Red, or b fixed cells stained with antibodies against TOMM20 (green, mitochondria) and LAMP1 (blue, lysosomes). Scalebars: 10 µm. Transfected fibroblasts, as identified by
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cytosolic mCherry signal, were characterized as described above for
the following cellular phenotypes: c mitochondrial morphology, d
lysosome morphology, e average mtDNA nucleoid size, f mtDNA
nucleoid counts, and g relative mtDNA copy number. Student T test
was performed as indicated for c, d, f, and g. K–S test was performed
to determine statistical significance for e. *p < 0.05, **p < 0.01,
***p < 0.0001

Acta Neuropathologica (2019) 138:1013–1031

of α-dystroglycan on muscle immunohistochemistry and
western blot, which would be normal in MSTO1-related
disease. In fact, immunofluorescence analysis of the muscle biopsy from P8 (p.(Phe217Leu); p,(Asp236His) and P9
(p.(Tyr478Cys); missing) showed normal α-dystroglycan
glycoepitope staining (data not shown). The other highly
relevant differential diagnosis with a reminiscent clinical
spectrum is Marinesco-Sjogren syndrome (MSS) caused by
bi-allelic mutations in SIL1. MSS is characterized by intellectual disability, early onset cataracts, ataxia with cerebellar
atrophy and myopathy. The absence of cataracts and severe
intellectual disability appear to distinguish MSTO1-related
disorders from MSS. Approximately 60% of patients with
the classic clinical features of MSS harbour SIL1 pathogenic variants, whereas only 3% (1/37) of those with atypical features have readily identifiable SIL1 pathogenic variants. Notably, in the study of SIL1 negative, atypical MSS
patients, one patient was ultimately diagnosed with an AGKrelated mtDNA depletion syndrome [26]. Therefore, it is
possible that other atypical MSS patients may also harbour
pathogenic MSTO1 variants. In order to help facilitate an
accurate genetic diagnosis, MSTO1 should be included in
targeted next-generation-based neuromuscular, mitochondrial and ataxia-related panels, where MSTO1 is currently
not included.
In this cohort we report six novel MSTO1 missense variants, a single base pair deletion and a large genomic deletion. Variants are scattered throughout the MSTO1 gene and
do not preferentially impact specific domains. We identified apparent recurring variants in three specific residues
(p.(Phe217Leu), p.(Arg279His) and p.(Asp236His/Gly)).
The p.(Arg279His) variant was previously reported as pathogenic in three families in heterozygosity with a truncating
allele [23, 31]. There is one individual listed in ExAC who is
homozygous for the p.(Arg279His) variant, which would be
unusual for a childhood-onset disease [29]. It is, therefore,
likely that in its own right this may be a much milder pathogenic allele that needs to occur in compound heterozygosity
with a more severe allele in order to manifest as early-onset
MSTO1-deficiency [23]. As noted, all patients thus presented with a remarkably homogeneous phenotype; therefore, no clear genotype–phenotype correlations emerged for
recessive MSTO1 variants beyond the p.(Arg279His) observation, and the absence of bi-allelic null mutations.
The MSTO1 gene is part of a large tandem segmental
duplication of approximately 240 kb located on chromosome 1q22. This arrangement is the result of an evolutionary duplication event estimated to have occurred 37 million
years ago in the human evolutionary lineage [28], which
also resulted in the derivation of the pseudogene MSTO2P
(NR_024117). This locus generates a long non-coding RNA
with a nucleotide identity degree of 99.5% and 98.1% of

1027

exonic and intronic regions, respectively [28]. This high
sequence similarity results in ambiguity of alignment of the
short-read sequences typically generated with next-generation based genetic testing approaches, as the alignment of
short reads to their proper genomic location maps equally
well with both MSTO1 and MSTO2P. Consequently, the
coverage of MSTO1 is significantly reduced in WES, WGS
and RNA-seq data from our patients, resulting in diagnostic
challenges. In fact, even with targeted Sanger sequencing it
can be challenging to unambiguously sequence MSTO1
without contribution of the pseudogene sequence. In this
context we also report the first presumed multi-exon deletion
of MSTO1, which, as expected, was not identified through
WES. In this patient [P7; (p.(Leu450Phe); deletion)], WES
identified an apparently homozygous MSTO1 missense variant in the absence of consanguinity; however, subsequent
WGS and RNA sequencing failed to identify the deletion
due to the inherent difficulties of mapping highly homologous regions. Targeted array CGH analysis with exon-level
resolution was able to identify the exon 9-14 deletion. Given
the duplicated and thus highly similar regions in this analysis, there were only three probes discriminating MSTO1
from MSTO2P; therefore, the mapping of the deletions to
MSTO1 is still ambiguous. Given the diagnostic confidence
in the disease phenotype, the reduced MSTO1 protein in this
patient’s fibroblasts and the previously identified rare, predicted to be damaging missense MSTO1 variant, we suspect
that the deletion is likely encompassing MSTO1. In contrast,
in patient P9 (p.(Tyr478Cys); missing), who also presented
with the disease phenotype and reduced MSTO1 protein
levels, extensive next-generation based-sequencing including array CGH analysis only yielded a single heterozygous
rare, predicted to be damaging missense MSTO1 variant. A
pathogenic variant on the other allele was not readily detectable with available technology, suggesting a more complex
genomic re-arrangement which may be copy number neutral. Validation work is in progress; however, this work is
significantly complicated by the high sequence similarity
between the duplicated genomic regions of the locus. Thus
proper diagnosis of MSTO1-deficiency may require specialized sequencing strategies, triggered by proper phenotypic
recognition through detailed clinical examination, brain MRI
and if needed MSTO1 protein analysis in fibroblasts [15].
In all seven novel MSTO1 fibroblast lines characterized,
MSTO1 protein was reduced (Fig. 3a), and mitochondrial
network fragmentation was observed (Fig. 4). Consistent
with our findings, it has been shown previously that the levels of the mitochondrial fusion proteins MFN1/2 and OPA1
are not affected in MSTO1 patient cells (Fig. 3b), [16], suggesting that the observed fragmented mitochondrial network
phenotype in patient cells is related to MSTO1-deficiency.
While defects in mitochondrial fusion have been linked
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to abnormalities in mtDNA, the specific consequences of
pathogenic MSTO1 variants regarding mtDNA integrity
have not been thoroughly investigated thus far [47]. Of the
previous MSTO1 studies, three did not investigate mtDNA
[16, 31]. Meanwhile, Nasca et al. reported mtDNA depletion in muscle from patient A1 and fibroblasts from patients
A1 and A2 (sisters), while mtDNA nucleoid size was not
quantified [36]. Analysis of mtDNA copy number across
our patient cohort now provides further insights into the
role of impaired mitochondrial fusion and mtDNA depletion in MSTO1-deficient patient cells. It would be of interest
to study this phenomenon in muscle tissue from MSTO1deficient patients, which unfortunately were not available
in this cohort.
While the mechanistic link between mitochondrial fusion/
fission dynamics and loss of mtDNA content remains unresolved, the present study adds another mitochondrial fusion
protein, MSTO1 to the list of mitochondrial dynamics proteins that are implicated in the maintenance of mtDNA
content. Our observation of enlarged nucleoids using PicoGreen staining is of interest in this context. The enlarged
nucleoids could reflect changes in the topology of mtDNA
that affect the ability of the dye to intercalate [20]. Alternatively, impaired segregation of mtDNA nucleoids, which
typically contain only a single copy of the mtDNA genome
[27], could lead to multiple mtDNA molecules within close
spatial proximity that appear as larger nucleoids [8]. We
favour the latter hypothesis given that loss of fusion is
known to impair nucleoid distribution with some mitochondrial fragments containing a relatively higher concentration
of mtDNA molecules while others completely lack mtDNA
[10], which we also observe in MSTO1 fibroblasts (Fig. 4a).
Meanwhile, recent work suggesting that reduced fusion
causes mtDNA depletion due to insufficient distribution of
the mtDNA replication machinery [44] is also consistent
with our findings in MSTO1 fibroblasts. In particular, the
fact that we see a full recovery of mitochondrial and lysosome morphology at 48 h, but only a partial recovery of
mtDNA (in the form of restoration of nucleoid size), further
suggests that impairments in mitochondrial dynamics are
upstream of mtDNA depletion in MSTO1 patient fibroblasts.
Nonetheless, the exact link between mtDNA copy number
and enlarged nucleoids remains unresolved.
It is also notable that mitochondrial fission was recently
shown to be important for mtDNA nucleoid segregation
following mtDNA replication [30] and that impairments in
fission are known to lead to enlarged nucleoid structures
[8]. Taken together, these observations provide further evidence that mitochondrial fusion and fission are important for
mtDNA segregation and distribution. We posit that altered
distribution and segregation of mtDNA (i.e. nucleoid clumping), in conjunction with reduced mitochondrial fusion,
impairs mtDNA maintenance leading to mtDNA depletion.
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Importantly, the degree of mtDNA depletion we see in
MSTO1 patient fibroblasts (30–70% of the normal content)
is consistent with the levels of mtDNA depletion reported
in fibroblasts from OPA1 or MFN2 patients [41, 46, 49]
as well as in mtDNA depletion syndromes (Fig. 6) [38].
The clinical significance of this observation requires further studies as the remarkably consistent and homogenous
phenotype of recessive MSTO1-related disease reported
within our cohort is in contrast to the frequently highly variable clinical spectrum observed in mitochondrial diseases
with childhood onset due to either nuclear DNA or mtDNA
pathogenic variants. Thus, the consequences of abnormal
mitochondrial dynamics caused by recessive MSTO1 pathogenic variants may be less susceptible to acutely variable
changes in metabolic demands, while likely incorporating
a developmental component given the early clinical manifestations and neuroimaging abnormalities. This consistent phenotype of MSTO1-deficiency reported to date also
seems in contrast to the single family with a dominantly
acting MSTO1 variant in whom psychiatric manifestations
including schizophrenia and autism were leading clinical
features, while muscle weakness was mild and cerebellar
involvement was not reported [16], thus suggesting a different underlying pathogenic mechanism. It is notable that
the pathogenic recessive variants in MSTO1 investigated to
date seem to impair protein stability in fibroblasts, which
is consistent with a loss of function mechanism, while not
providing further insight into functional subdomains of the
protein. Since haploinsufficiency, as is present in some of
the heterozygous parents in our cohort, does not cause a
clinical phenotype, the mechanism for the dominantly acting
heterozygous mutation may be dominant-negative in nature
with perhaps different physiological consequences [16].
Despite evidence for the role of MSTO1 in mitochondrial fusion, the molecular structure of the MSTO1 protein
and the exact mechanism by which MSTO1 performs this
function directly or via mediators are still unknown. Our
findings that bi-allelic loss-of-function variants in MSTO1
result in fragmented mitochondrial networks with mtDNA
depletion and nucleoid abnormalities highlight a previously
unappreciated role for MSTO1 in the maintenance of the
mitochondrial genome. Taken together, our findings newly
characterize MSTO1-deficiency as a syndrome of both
impaired mitochondrial fusion as well as of mtDNA depletion, while clinically manifesting with a remarkably consistent phenotype.
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